Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

Dennis A Eichenauer^{1

2}, Ina Bühnen^{1

2}, Annette Plütschow^{1

2}, Carsten Kobe^{2

3}, Markus Dietlein^{2

3}, Clemens-Martin Wendtner⁴, Sven Thorspecken⁴, Max S Topp⁵, Mareike Mauser⁵, Bastian von Tresckow^{2

6}, Michael Fuchs^{1

2}, Peter Borchmann^{1

2}, Andreas Engert^{1

2}

Affiliations

¹ First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
³ Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
⁴ Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.
⁵ Second Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
⁶ Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Clinical Trial

Dennis A Eichenauer et al. Hematol Oncol. 2022 Oct.

. 2022 Oct;40(4):801-804.

doi: 10.1002/hon.2986. Epub 2022 Mar 24.

¹ First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
³ Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
⁴ Department of Hematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.
⁵ Second Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany.
⁶ Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

No abstract available

Keywords: Btk; NLPHL; ibrutinib; relapse; salvage therapy.

References

1. Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematol Am Soc Hematol Educ Progr. 2017;2017(1):324-328. https://doi.org/10.1182/asheducation-2017.1.324
1. Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020;136(26):2987-2993. https://doi.org/10.1182/blood.2019004044
1. Eichenauer DA, Plutschow A, Schroder L, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132(14):1519-1525. https://doi.org/10.1182/blood-2018-02-836437
1. Strati P, Cheng PTM, Steiner RE, et al. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021;192(3):192-567. https://doi.org/10.1111/bjh.17281
1. Akhtar S, Montoto S, Boumendil A, et al. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation-lymphoma working party. Am J Hematol. 2018;93(1):40-46. https://doi.org/10.1002/ajh.24927